It Seems Nuvectra Corporation (NVTR) Will Go Up. Just Reaches 52-Week High

June 15, 2018 - By Marie Mckinney

Nuvectra Corporation (NASDAQ:NVTR) Logo

The stock of Nuvectra Corporation (NASDAQ:NVTR) hit a new 52-week high and has $23.34 target or 6.00 % above today’s $22.02 share price. The 7 months bullish chart indicates low risk for the $311.66M company. The 1-year high was reported on Jun, 15 by Barchart.com. If the $23.34 price target is reached, the company will be worth $18.70M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock decreased 3.42% or $0.78 during the last trading session, reaching $22.02. About 169,196 shares traded or 9.43% up from the average. Nuvectra Corporation (NASDAQ:NVTR) has risen 66.40% since June 15, 2017 and is uptrending. It has outperformed by 53.83% the S&P500.

Analysts await Nuvectra Corporation (NASDAQ:NVTR) to report earnings on August, 14. They expect $-0.92 earnings per share, up 14.02 % or $0.15 from last year’s $-1.07 per share. After $-0.84 actual earnings per share reported by Nuvectra Corporation for the previous quarter, Wall Street now forecasts 9.52 % negative EPS growth.

Another recent and important Nuvectra Corporation (NASDAQ:NVTR) news was published by Globenewswire.com which published an article titled: “Nuvectra to Present at Two Upcoming Investor Conferences” on May 17, 2018.

Nuvectra Corporation, a neuromodulation medical device company, develops and commercializes its neurostimulation technology platform for the treatment of various disorders in neuroscience and clinical markets in Europe. The company has market cap of $311.66 million. The firm offers Algovita spinal cord stimulation system that is used for the treatment of chronic pain of the trunk and limbs. It currently has negative earnings. It also provides neural interface systems, including microelectrode arrays, probes, and electrode instrumentation and accessories; and develops Virtis, a sacral nerve stimulation system for the treatment of chronic urinary retention and the symptoms of overactive bladder.

Nuvectra Corporation (NASDAQ:NVTR) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: